Provided by Tiger Trade Technology Pte. Ltd.

Vor Biopharma Inc.

13.16
+1.099.03%
Post-market: 13.180.0200+0.15%19:49 EST
Volume:1.05M
Turnover:13.82M
Market Cap:546.40M
PE:-0.03
High:13.80
Open:12.31
Low:12.25
Close:12.07
52wk High:65.80
52wk Low:2.62
Shares:41.52M
Float Shares:18.97M
Volume Ratio:1.13
T/O Rate:5.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-386.8600
EPS(LYR):-34.0333
ROE:-125.43%
ROA:-144.27%
PB:-0.25
PE(LYR):-0.39

Loading ...

Company Profile

Company Name:
Vor Biopharma Inc.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
154
Office Location:
100 Cambridgepark Drive,Suite 101,Cambridge,Massachusetts,United States
Zip Code:
02140
Fax:
- -
Introduction:
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Directors

Name
Position
Jean Paul Kress
Chief Executive Officer, President and Chairman of the Board
Andrew Levin
Independent Director
Daniella Beckman
Independent Director
Erez Kalir
Independent Director
Fouad Namouni
Independent Director
Wouter Joustra
Independent Director
Alexander Cumbo
Director
Michel Detheux
Director

Shareholders

Name
Position
Jean Paul Kress
Chief Executive Officer, President and Chairman of the Board
Sandesh Mahatme
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Amy Quinlan
Vice President, Finance